Prince Akwasi Mensah

Array ( [id] => 6847493 [patent_doc_number] => 20030166660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-04 [patent_title] => 'Combinations comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and at least one telomerase inhibitor' [patent_app_type] => new [patent_app_number] => 10/272837 [patent_app_country] => US [patent_app_date] => 2002-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5682 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20030166660.pdf [firstpage_image] =>[orig_patent_app_number] => 10272837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7169932 [patent_doc_number] => 20040077731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-04-22 [patent_title] => 'Method and compound for antagonizing inhibition effects of alcohol on cell adhesion' [patent_app_type] => new [patent_app_number] => 10/270551 [patent_app_country] => US [patent_app_date] => 2002-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8427 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0077/20040077731.pdf [firstpage_image] =>[orig_patent_app_number] => 10270551 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7469276 [patent_doc_number] => 20040102423 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-05-27 [patent_title] => 'Spironolactone and angiotensin II antagonist combination therapy for treatment of congestive heart failure' [patent_app_type] => new [patent_app_number] => 10/271362 [patent_app_country] => US [patent_app_date] => 2002-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15031 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0102/20040102423.pdf [firstpage_image] =>[orig_patent_app_number] => 10271362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1096472 [patent_doc_number] => 06821995 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-11-23 [patent_title] => 'Method of treating batten disease' [patent_app_type] => B1 [patent_app_number] => 10/148859 [patent_app_country] => US [patent_app_date] => 2002-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 11 [patent_no_of_words] => 3013 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/821/06821995.pdf [firstpage_image] =>[orig_patent_app_number] => 10148859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6693032 [patent_doc_number] => 20030040464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-27 [patent_title] => 'Method of treating or preventing attention defecit hyperactivity disorder' [patent_app_type] => new [patent_app_number] => 10/255450 [patent_app_country] => US [patent_app_date] => 2002-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9136 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0040/20030040464.pdf [firstpage_image] =>[orig_patent_app_number] => 10255450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1050160 [patent_doc_number] => 06861439 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2005-03-01 [patent_title] => 'Treatment of cerebrovascular disease' [patent_app_type] => utility [patent_app_number] => 10/254197 [patent_app_country] => US [patent_app_date] => 2002-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 14294 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/861/06861439.pdf [firstpage_image] =>[orig_patent_app_number] => 10254197 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6847494 [patent_doc_number] => 20030166661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-04 [patent_title] => 'L-arginine and phosphodiesterase (PDE) inhibitor synergism' [patent_app_type] => new [patent_app_number] => 10/253404 [patent_app_country] => US [patent_app_date] => 2002-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 12581 [patent_no_of_claims] => 44 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0166/20030166661.pdf [firstpage_image] =>[orig_patent_app_number] => 10253404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6773807 [patent_doc_number] => 20030017145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-01-23 [patent_title] => 'Treatment and prevention of reactive oxygen metabolite-mediated cellular damage' [patent_app_type] => new [patent_app_number] => 10/251420 [patent_app_country] => US [patent_app_date] => 2002-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11789 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0017/20030017145.pdf [firstpage_image] =>[orig_patent_app_number] => 10251420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6740888 [patent_doc_number] => 20030158257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-08-21 [patent_title] => 'Method for activating the lipid catabolic metabolism in enteric epithelium and improving the lipid metabolism in enteric epithelium' [patent_app_type] => new [patent_app_number] => 10/238720 [patent_app_country] => US [patent_app_date] => 2002-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 13381 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0158/20030158257.pdf [firstpage_image] =>[orig_patent_app_number] => 10238720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6788156 [patent_doc_number] => 20030139395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-07-24 [patent_title] => 'Combination of an adenosine A2a receptor antagonist and an antidepressant or anxiolytic' [patent_app_type] => new [patent_app_number] => 10/241120 [patent_app_country] => US [patent_app_date] => 2002-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9618 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0139/20030139395.pdf [firstpage_image] =>[orig_patent_app_number] => 10241120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6839160 [patent_doc_number] => 20030036500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-20 [patent_title] => 'Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists' [patent_app_type] => new [patent_app_number] => 10/233580 [patent_app_country] => US [patent_app_date] => 2002-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8710 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0036/20030036500.pdf [firstpage_image] =>[orig_patent_app_number] => 10233580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6818342 [patent_doc_number] => 20030069300 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-04-10 [patent_title] => 'Use of benzopyranols to treat neurological disorders' [patent_app_type] => new [patent_app_number] => 10/229982 [patent_app_country] => US [patent_app_date] => 2002-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3722 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0069/20030069300.pdf [firstpage_image] =>[orig_patent_app_number] => 10229982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6669381 [patent_doc_number] => 20030114365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-06-19 [patent_title] => 'Inhibitors of rotamase enzyme activity' [patent_app_type] => new [patent_app_number] => 10/228312 [patent_app_country] => US [patent_app_date] => 2002-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 12280 [patent_no_of_claims] => 56 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0114/20030114365.pdf [firstpage_image] =>[orig_patent_app_number] => 10228312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1240359 [patent_doc_number] => 06686383 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2004-02-03 [patent_title] => 'Prophylactic or therapeutic drug for renal diseases' [patent_app_type] => B2 [patent_app_number] => 10/227537 [patent_app_country] => US [patent_app_date] => 2002-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6294 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/686/06686383.pdf [firstpage_image] =>[orig_patent_app_number] => 10227537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6766203 [patent_doc_number] => 20030100603 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-05-29 [patent_title] => 'Tocopherol enriched compositions and amelioration of inflammatory symptoms' [patent_app_type] => new [patent_app_number] => 10/227094 [patent_app_country] => US [patent_app_date] => 2002-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22685 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0100/20030100603.pdf [firstpage_image] =>[orig_patent_app_number] => 10227094 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6736054 [patent_doc_number] => 20030013689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-01-16 [patent_title] => 'Method for treating pain' [patent_app_type] => new [patent_app_number] => 10/224224 [patent_app_country] => US [patent_app_date] => 2002-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4248 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0013/20030013689.pdf [firstpage_image] =>[orig_patent_app_number] => 10224224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6839213 [patent_doc_number] => 20030036553 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-20 [patent_title] => 'Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis' [patent_app_type] => new [patent_app_number] => 10/217843 [patent_app_country] => US [patent_app_date] => 2002-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6685 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0036/20030036553.pdf [firstpage_image] =>[orig_patent_app_number] => 10217843 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6669519 [patent_doc_number] => 20030114503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-06-19 [patent_title] => 'Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer' [patent_app_type] => new [patent_app_number] => 10/217108 [patent_app_country] => US [patent_app_date] => 2002-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8342 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0114/20030114503.pdf [firstpage_image] =>[orig_patent_app_number] => 10217108 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6538153 [patent_doc_number] => 20020193416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-12-19 [patent_title] => 'Synergistic tumorcidal response induced by histamine' [patent_app_type] => new [patent_app_number] => 10/217254 [patent_app_country] => US [patent_app_date] => 2002-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6210 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0193/20020193416.pdf [firstpage_image] =>[orig_patent_app_number] => 10217254 [rel_patent_id] =>[rel_patent_doc_number] =>)